In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Supplemental individuals are going to be enrolled in the determined monotherapy dosign routine. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "insert-on" therapy. https://isaaci306mjc9.vigilwiki.com/user